The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 354:2498-2500 June 8, 2006 Number 23
NextNext

ACE Inhibitors and Congenital Anomalies
J.M. Friedman, M.D., Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Cooper, W. O.
-PubMed Citation
Angiotensin-converting–enzyme (ACE) inhibitors are among the most widely prescribed antihypertensive agents in the United States, but when used in the second half of pregnancy, they can cause oligohydramnios, fetal growth retardation, pulmonary hypoplasia, joint contractures, hypocalvaria and neonatal renal failure, hypotension, and death.1,2,3 These effects result from blockade of the conversion of angiotensin I to angiotensin II in the developing fetal kidneys.3 A strikingly similar pattern of fetal anomalies has been reported after treatment of women in the second or third trimester of pregnancy with angiotensin II–receptor antagonists,1,4 drugs that block the fetal renin–angiotensin system at a different point.

In . . . [Full Text of this Article]


Source Information

From the Department of Medical Genetics, University of British Columbia, Vancouver, Canada.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.